This article exposes how Group Purchasing Organizations erect invisible barriers that sideline innovative small orthopedic companies, costing patients safer, cheaper solutions—and arms reformers with the facts to dismantle the monopoly.
Picture this: You've sunk years and millions into a cutting-edge orthopedic device—maybe a 3D-printed knee with antimicrobial coatings that slashes infection rates by 20% and costs 30% less than the legacy giants.
Clinical trials? Gold standard.
FDA clearance? Check.
But when you knock on the door of a major hospital system, the response isn't "Show us the...
